.After antibody-drug conjugate (ADC) expert Seagen was actually sold to Pfizer in 2014 for a whoppin...
.On the heels of a phase 3 win that failed to make an impression on financiers, Ironwood Pharmaceuti...
.Don't stop Monte Rosa Rehabs right now. The Boston-based biotech is enjoying after authorizing a ha...
.Welcome to this week's Chutes & Ladders, our roundup of considerable management hirings, shootin...
.Celebrating his company's upsized going public (IPO), Septerna chief executive officer Jeffrey Fine...
.AbbVie has come back to the source of its own antipsychotic giant Vraylar looking for yet another r...
.GenSight Biologics is actually full weeks away from losing loan. Again. The biotech simply has enou...
.Monopar Therapies is recuperating a medication coming from the dump of AstraZeneca's unusual diseas...
.Along with new information out on Arcus Biosciences' speculative HIF-2a inhibitor, one group of ana...
.After forming a gene treatment alliance along with Dyno Therapies in 2020, Roche is back for even m...
.Lundbeck is lowering the book market value of its own $250 million Abide Therapies acquistion in ac...
.The combination of real-world information (RWD) in to procedure usefulness and web site choice has ...
.At this year's Tough Biotech Top in Boston ma, our company caught up with leaders in the biotech bu...
.Merck & Co. is actually taking down $30 thousand in advance to buy Yale spinout Modifi Bioscienc...
.Alpha-9 Oncology has actually raised a $175 thousand collection C cycle to stake its own clinical-s...
.Eye medicine producer Ocuphire Pharma is getting genetics therapy programmer Piece Genetic makeup i...
.Roche's severe coughing plan has sputtered to a standstill. The drugmaker, which axed the plan afte...
.Gilead Sciences and Merck & Co. have assisted their once-weekly HIV combination treatment past y...
.Lykos Therapies might possess shed three-quarters of its team following the FDA's being rejected of...
.Septerna might be yet to make known "any purposeful professional data," however the biotech clearly...